Denali Therapeutics Inc (DNLI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Denali Therapeutics Inc (DNLI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8143
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Denali Therapeutics Inc (Denali Therapeutics) is a clinical-stage biopharmaceutical company that focuses on the development of therapeutics for the treatment of neurodegenerative diseases. The company’s proprietary drug delivery platform technologies include antibody transport vehicle and enzyme transport vehicle designed to deliver large molecules across the blood-brain barrier (BBB). Its pipeline products are intended for the treatment of Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, lysosomal storage disorder MPS II, neurodegeneration, amyotrophic lateral sclerosis and other indications. The company has development and commercialization rights to all of its programs, including the programs partnered with Takeda. Denali Therapeutics is headquartered in South San Francisco, California, the US.

Denali Therapeutics Inc (DNLI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Denali Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Denali Therapeutics Raises USD130 Million in Series B Financing 12
Denali Therapeutics Raises USD217 Million in Venture Financing 13
Denali Therapeutics Raises USD217 Million in Venture Financing 15
Partnerships 16
Centogene and Denali Therapeutics Enter into Agreement 16
AbCellera Biologics Enters into Agreement with Denali Therapeutics 17
Parkinson’s Institute and Denali Therapeutics Enter into Agreement 18
Lonza Enters into Agreement with Denali Therapeutics 19
Takeda Pharma and Denali Therapeutics to Enter into Agreement 20
Denali Therapeutics Enters into Research Agreement with Blaze Bioscience 21
Denali Therapeutics Enters into Research Agreement with ALS Therapy Development Institute 22
Licensing Agreements 23
Denali Therapeutics Enters into Licensing Agreement with Washington University School of Medicine 23
Denali Therapeutics Expands Licensing And Collaboration Agreement with F-star 24
Denali Therapeutics Enters Into Licensing Agreement With Genentech 26
Equity Offering 27
Denali Therapeutics Raises USD287.5 Million in IPO 27
Denali Therapeutics Raises USD30 Million in Private Placement of Shares 29
Denali Therapeutics Raises USD7.6 Million in Private Placement of Shares 30
Denali Therapeutics Raises USD88.7 Million in Private Placement of Shares 31
Denali Therapeutics Raises USD122.3 Million in Private Placement of Shares 32
Denali Therapeutics Raises USD35 Million in Private Placement of Shares 33
Denali Therapeutics Raises USD47 Million in Private Placement of Shares 34
Denali Therapeutics Raises USD9.7 Million in Private Placement of Shares 35
Denali Therapeutics Raises USD0.1 Million in Private Placement of Shares 36
Denali Therapeutics Raises USD39.1 Million in Private Placement of Shares 37
Acquisition 38
Denali Therapeutics to Acquire F-star Gamma 38
Denali Therapeutics Acquires Incro Pharma 39
Denali Therapeutics Inc – Key Competitors 40
Denali Therapeutics Inc – Key Employees 41
Denali Therapeutics Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Aug 09, 2018: Denali Therapeutics reports second quarter 2018 financial results 43
May 11, 2018: Denali Therapeutics Reports First Quarter 2018 Financial Results 44
Mar 19, 2018: Denali Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results 45
Corporate Communications 46
Aug 07, 2018: Denali Therapeutics Appoints Dana Andersen, Ph.D., as Chief Technical and Manufacturing Officer 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Denali Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Denali Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Denali Therapeutics Raises USD130 Million in Series B Financing 12
Denali Therapeutics Raises USD217 Million in Venture Financing 13
Denali Therapeutics Raises USD217 Million in Venture Financing 15
Centogene and Denali Therapeutics Enter into Agreement 16
AbCellera Biologics Enters into Agreement with Denali Therapeutics 17
Parkinson's Institute and Denali Therapeutics Enter into Agreement 18
Lonza Enters into Agreement with Denali Therapeutics 19
Takeda Pharma and Denali Therapeutics to Enter into Agreement 20
Denali Therapeutics Enters into Research Agreement with Blaze Bioscience 21
Denali Therapeutics Enters into Research Agreement with ALS Therapy Development Institute 22
Denali Therapeutics Enters into Licensing Agreement with Washington University School of Medicine 23
Denali Therapeutics Expands Licensing And Collaboration Agreement with F-star 24
Denali Therapeutics Enters Into Licensing Agreement With Genentech 26
Denali Therapeutics Raises USD287.5 Million in IPO 27
Denali Therapeutics Raises USD30 Million in Private Placement of Shares 29
Denali Therapeutics Raises USD7.6 Million in Private Placement of Shares 30
Denali Therapeutics Raises USD88.7 Million in Private Placement of Shares 31
Denali Therapeutics Raises USD122.3 Million in Private Placement of Shares 32
Denali Therapeutics Raises USD35 Million in Private Placement of Shares 33
Denali Therapeutics Raises USD47 Million in Private Placement of Shares 34
Denali Therapeutics Raises USD9.7 Million in Private Placement of Shares 35
Denali Therapeutics Raises USD0.1 Million in Private Placement of Shares 36
Denali Therapeutics Raises USD39.1 Million in Private Placement of Shares 37
Denali Therapeutics to Acquire F-star Gamma 38
Denali Therapeutics Acquires Incro Pharma 39
Denali Therapeutics Inc, Key Competitors 40
Denali Therapeutics Inc, Key Employees 41
Denali Therapeutics Inc, Subsidiaries 42

List of Figures
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Denali Therapeutics Inc (DNLI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TonenGeneral Sekiyu K.K. (5012)-石油・ガス分野:企業M&A・提携分析
    Summary TonenGeneral Sekiyu K.K. (TonenGeneral) is an energy company that imports, refines and processes crude oil. It also manufactures, distributes and markets petroleum and petrochemical products. The company’s product portfolio includes lubricants, naphtha, sulphur, kerosene, hydrocarbon resin, …
  • TheraDiag SA (ALTER):医療機器:M&Aディール及び事業提携情報
    Summary Theradiag SA (Theradiag), formerly Biomedical Diagnostics SA, is a biotechnology company that develops, manufactures, and markets vitro diagnostic products. The company offers product for the diagnostics of auto-immune diseases, allergies and infectious diseases. It develops product panels f …
  • Efore Oyj (EFO1V):企業の財務・戦略的SWOT分析
    Efore Oyj (EFO1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Hogan Lovells International LLP:企業の戦略的SWOT分析
    Hogan Lovells International LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Fugro GeoServices Ltd:企業の戦略的SWOT分析
    Fugro GeoServices Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Tokuyama Corporation (4043):企業の財務・戦略的SWOT分析
    Tokuyama Corporation (4043) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • PharmAbcine Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary PharmAbcine Inc (PharmAbcine) is a biotechnology company that discovers and develops human therapeutic monoclonal antibodies. The company offers products such as bi-specific MAB and lead MAB products. It provides services such as binding test by ELISA, screening by ELISA, mono-phage Ab seque …
  • MTN Group Ltd (MTN):企業の財務・戦略的SWOT分析
    MTN Group Ltd (MTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Newmont Mining Corporation:企業のM&A・事業提携・投資動向
    Newmont Mining Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Newmont Mining Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • QBE Insurance (Vietnam) Company Ltd:企業の戦略的SWOT分析
    QBE Insurance (Vietnam) Company Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Wacker Neuson Se
    Wacker Neuson Se - Strategy, SWOT and Corporate Finance Report Summary Wacker Neuson Se - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Koninklijke Philips NV (PHIA):企業の製品パイプライン分析
    Summary Koninklijke Philips NV (Philips) is a diversified technology company that develops and manufactures medical systems and consumer electronics products. The company offers products and solutions in the areas of diagnostic imaging, enterprise diagnostic informatics, image-guided therapy, ultras …
  • Magnit:企業の戦略・SWOT・財務分析
    Magnit - Strategy, SWOT and Corporate Finance Report Summary Magnit - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Lannett Company Inc (LCI):企業の財務・戦略的SWOT分析
    Lannett Company Inc (LCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • ADDvise Group AB (ADDV A):医療機器:M&Aディール及び事業提携情報
    Summary ADDvise Group AB (ADDvise), formerly ADDvise Lab Solutions AB, is a medical device company that manufactures and markets healthcare and laboratory equipment. The company offers laboratory products such as laboratory equipments, furnishings, safety ventilation, centrifuges, climate chambers, …
  • Hester Biosciences Ltd (HESTERBIO):企業の財務・戦略的SWOT分析
    Hester Biosciences Ltd (HESTERBIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Elavon Inc:企業の戦略・SWOT・財務分析
    Elavon Inc - Strategy, SWOT and Corporate Finance Report Summary Elavon Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • PDS Biotechnology Corp-製薬・医療分野:企業M&A・提携分析
    Summary PDS Biotechnology Corp (PDS Biotechnology) is a biopharmaceutical company that develops immunotherapies and vaccines for cancer and infectious disease. The company uses versamune technology, which is immunostimulatory nanoparticle vaccine platform used for the development of cancer immunothe …
  • Dermira Inc (DERM):医療機器:M&Aディール及び事業提携情報
    Summary Dermira Inc (Dermira) is a biopharmaceutical company that identifies, develops and commercializes therapeutic solutions for the treatment of dermatologic diseases, such as hyperhidrosis, acne vulgaris and atopic dermatitis. The company’s product includes QBREXZA (glycopyrronium) cloth, an an …
  • Eaton Corporation Plc (ETN):電力:M&Aディール及び事業提携情報
    Summary Eaton Corporation Plc (Eaton) is a power management company. It designs, develops, and sells products and services, which help customers manage electrical, hydraulic and mechanical power more reliably, efficiently, safely, and sustainably. Eaton serves customers in the utility, governmental, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆